Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 1/2 3Phase 1 3

Status

Completed 3Active not recruiting 2Withdrawn 1Terminated 1

Sponsor Class

INDUSTRY 3

Study Type

Interventional 3

Sponsor

Cancer Type

Other hematologic neoplasm 2Myeloid 2Lymphoid 1

Conditions

Myelodysplastic Syndromes 2Leukemia 2Neoplasms 1Neoplasm Metastasis 1Lymphoma, Non-Hodgkin 1

Interventions

Paclitaxel 292Gemcitabine 254Carboplatin 254Cisplatin 251Radiotherapy 219Cyclophosphamide 218Irinotecan 184pembrolizumab 181Docetaxel 174Bevacizumab 166Capecitabine 148Nivolumab 141Fluorouracil 132Dexamethasone 125Bortezomib 123Oxaliplatin 115Cytarabine 113Erlotinib Hydrochloride 112Temozolomide 110Sorafenib 110Doxorubicin 106Rituximab 105Leucovorin 105Etoposide 105Filgrastim 99Everolimus 97Lenalidomide 95Pemetrexed 90Ipilimumab 90fludarabine phosphate 84

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Phase 1 × Completed × mocetinostat × Clear all
NCT00323934 2015-01-08

Study of MGCD0103 Given Three-Times Weekly in Patients With Advanced Solid Tumors or Non-Hodgkin's Lymphoma

Mirati Therapeutics Inc.

Phase 1 Completed
42 enrolled
Lymphoid

Lymphoma, Non-Hodgkin, Neoplasm Metastasis, Neoplasms

NCT00324129 2015-01-08

A Phase I Study of MGCD0103 Given Three-Times Weekly In Patients With Leukemia Or Myelodysplastic Syndromes

Mirati Therapeutics Inc.

Phase 1 Completed
29 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

NCT00324194 2015-01-08

A Phase I Study of MGCD0103 Given Twice Weekly in Patients With Leukemia or Myelodysplastic Syndromes

Mirati Therapeutics Inc.

Phase 1 Completed
25 enrolled
MyeloidOther hematologic neoplasm

Leukemia, Myelodysplastic Syndromes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡